Reports Q2 adjusted EBITDA C$15.37M vs. C$10.14M last year. “Aurora’s quarterly performance highlights our continued focus on profitable growth. We achieved record net revenue1 for global medical cannabis representing a 15% year-over-year increase, while adjusted EBITDA1 rose 52%. These strong results affirm our strategic prioritization of medical cannabis as the industry’s most compelling growth area,” said Executive Chairman and Chief Executive Officer, Miguel Martin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Options Volatility and Implied Earnings Moves This Week, November 03 – November 07, 2025
- Aurora Cannabis Schedules Q2 2026 Investor Conference Call
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
- Cannabis Stocks Jump as Trump Endorses Cannabidiol for Elderly Care
- Tilray up after Trump posts video on medical benefits of CBD for seniors